Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?

Trends Endocrinol Metab. 2011 Oct;22(10):404-11. doi: 10.1016/j.tem.2011.05.004. Epub 2011 Jul 7.

Abstract

Phosphodiesterase type 5 (PDE5) is expressed in many tissues (e.g. heart, lung, pancreas, penis) and plays a specific role in hydrolyzing cyclic guanosine monophosphate (cGMP). In adipocytes, cGMP regulates crucial functions by activating cGMP-dependent protein kinase (PKG). Interestingly, PDE5 was recently identified in adipose tissue, although its role remains unclear. Its inhibition, however, was recently shown to affect adipose differentiation and aromatase function. This review summarizes evidence supporting a role for the PDE5-regulated cGMP/PKG system in adipose tissue and its effects on adipocyte function. A better elucidation of the role of PDE5 in the adipocyte could reveal new therapeutic strategies for fighting obesity and metabolic syndrome.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipocytes / cytology
  • Adipocytes / enzymology*
  • Adipogenesis
  • Adipose Tissue / metabolism*
  • Animals
  • Cell Differentiation
  • Cyclic GMP / physiology
  • Cyclic GMP-Dependent Protein Kinases / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
  • Enzyme Activation
  • Humans
  • Insulin
  • Lipid Metabolism
  • Lipolysis
  • Obesity
  • Signal Transduction

Substances

  • Insulin
  • Cyclic GMP-Dependent Protein Kinases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Cyclic GMP